A 45-year-old woman with rheumatoid arthritis on methotrexate 20 mg/week and hydroxychloroquine continues to have active disease (DAS28-CRP = 4.8). Anti-CCP antibodies are strongly positive and RF is positive. What is the preferred next step per 2022 ACR RA guidelines?
- A Add leflunomide to make triple DMARD therapy (MTX + HCQ + LEF)
- B Add a TNF inhibitor (e.g., etanercept or adalimumab) as a biologic DMARD ✓
- C Switch to triple conventional DMARD therapy (MTX + HCQ + SSZ) before biologics
- D Add low-dose prednisolone 7.5 mg/day as long-term bridging therapy
Explanation
Per the 2022 ACR guidelines for RA management, when a patient has moderate-to-high disease activity (DAS28 > 3.2) despite combination conventional synthetic DMARD (csDMARD) therapy with methotrexate ± another csDMARD, adding a biologic DMARD (bDMARD) — specifically a TNF inhibitor — or a JAK inhibitor is recommended over further csDMARD combinations. The guideline conditionally recommends bDMARDs or targeted synthetic DMARDs over triple csDMARD therapy in this setting, though triple therapy (MTX + HCQ + SSZ) is an alternative for patients preferring to avoid biologics. Long-term low-dose steroids are not a preferred strategy and carry cumulative harm.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.